Berahyaluronidase alfa is a recombinant human hyaluronidase used to improve the absorption of subcutaneously co-administered drugs. It is used in a fixed-dose combination with pembrolizumab for subcutaneous injection.
- Mechanism
- Curator reviewed · 4 references
Berahyaluronidase alfa is a variant of human hyaluronidase PH20 that temporarily and locally breaks down hyaluronan by cleaving hyaluronic acid at the glucosaminidic bond between C1 of glucosamine and C4 of glucuronic acid. Hyaluronan is a polysaccharide and key component of the extracellular matrix of the subcutaneous tissue. The co-administration of hyaluronidases with other fluids or drugs improves the ability of these other compounds to permeate the extracellular space, thereby facilitating subcutaneous administration.
- Primary indication
- Berahyaluronidase alfa is an endoglycosidase administered in combination with pembrolizumab - under the brand name Keytruda QLEX - in order to improve pembrolizumab's subcutaneous absorption.Curator reviewed
- Formula / weight
- 49000.0 Da (nonreducing, deglycosylated conditions)
- First approval
- United States, 2025
- Also known as
- Berahyaluronidase alfa-pmph
- Code names
- MK-5180
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which companies are running trials of Berahyaluronidase alfa, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account